These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32887999)

  • 1. Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions.
    Sulkowski M; Wyles D
    Clin Infect Dis; 2021 Nov; 73(9):e3296-e3299. PubMed ID: 32887999
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct acting antivirals failure: cause and retreatment options.
    Parlati L; Pol S
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Vo-Quang E; Soulier A; Ndebi M; Rodriguez C; Chevaliez S; Leroy V; Fourati S; Pawlotsky JM;
    Hepatology; 2023 Aug; 78(2):607-620. PubMed ID: 36999537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Retreatment of direct-acting antiviral failures with the current first-line regimens for patients with chronic hepatitis C.
    Ogawa E
    Aliment Pharmacol Ther; 2024 Jul; 60(2):276-277. PubMed ID: 38881195
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two case reports of chronic hepatitis C retreatment].
    Rožnovský L; Mrázek J; Petroušová L; Orságová I; Kabieszová L; Konečná M; Kloudová A
    Klin Mikrobiol Infekc Lek; 2020 Sep; 26(3):96-98. PubMed ID: 33418597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
    Zarębska-Michaluk D; Buczyńska I; Simon K; Tudrujek-Zdunek M; Janczewska E; Dybowska D; Sitko M; Dobracka B; Jaroszewicz J; Pabjan P; Klapaczyński J; Laurans Ł; Mazur W; Socha Ł; Tronina O; Parczewski M; Flisiak R
    Can J Gastroenterol Hepatol; 2019; 2019():4029541. PubMed ID: 30941326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
    J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
    Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
    J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
    Dietz J; Spengler U; Müllhaupt B; Schulze Zur Wiesch J; Piecha F; Mauss S; Seegers B; Hinrichsen H; Antoni C; Wietzke-Braun P; Peiffer KH; Berger A; Matschenz K; Buggisch P; Backhus J; Zizer E; Boettler T; Neumann-Haefelin C; Semela D; Stauber R; Berg T; Berg C; Zeuzem S; Vermehren J; Sarrazin C;
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):195-198.e2. PubMed ID: 31706062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
    Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.
    Lee DH; Ryu SH; Myung HJ; Shin YJ; Lee SH; Park TY; Moon JS
    Korean J Gastroenterol; 2021 Feb; 77(2):88-91. PubMed ID: 33633000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
    Suda G; Nakai M; Sho T; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Baba M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Intern Med; 2019 Apr; 58(7):943-947. PubMed ID: 30568153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
    Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
    J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.
    Elhence A; Singh A; Anand A; Kumar R; Ashraf A; Kumar S; Pradhan D; Pathak P; Vaishnav M; Rajput MS; Banyal V; Nayak B; Shalimar
    J Med Virol; 2021 Aug; 93(8):4982-4991. PubMed ID: 33783006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.